Christian Henry has become general manager of the life sciences business unit of Illumina. His new appointment is in addition to his other positions of senior vice president and chief financial officer.
Elizabeth Brady has joined Illumina as vice president for global supply chain. She will be responsible for Illumina's global sourcing, planning, logistics, and distribution operations. Prior to joining the company, she was vice president of global supply chain for the cardiac rhythm management division of Boston Scientific. Brady holds a BS in business analysis and business economics from Indiana University.
Emily Winn-Deen has been appointed as Illumina's vice president for diagnostics development. She will be responsible for the development of diagnostics products at Illumina. Previously, she was president of Rx Dx Advisors, a consulting practice. Before that, she held vice president positions in genetics and oncology R&D, and in strategic development and business planning at Cepheid. In the past, she held senior R&D positions at Roche Molecular Systems, Applera, Oncor, and Bayer Diagnostics. Winn-Deen holds a PhD in chemistry from Boston University and a BA in chemistry from Lehigh University.
Michael Lutz has become the founding CEO of LifeCodexx, a new diagnostic spin-off from GATC Biotech (see story, this issue). Most recently, he was global general manager of Cogenics, which Beckman Coulter acquired last year. Previously, he was CEO of Epidauros and Sunyx, and held leadership positions at Novartis Pharma and Evotec.
Wera Hofmann has joined LifeCodexx as medical director. Most recently, she was managing director of the Association of German Human Geneticists, BVDH, a trade association. Until 2006, she led a diagnostic unit for BRCA testing at the Interdisciplinary Center for Hereditary Breast Cancer at the Max-Delbrück Center in Berlin.
Peter Pohl, Christof von Kalle, and Dirk Honold are members of LifeCodexx' supervisory board. Pohl is the co-founder and CEO of parent company GATC Biotech. Von Kalle is the director of the National Center for Tumor Diseases and head the translational oncology department at the German Cancer Research Center, both located in Heidelberg. Honold is a professor of financing at the Georg-Simon-Ohm University in Nürnberg, Germany. He is also the chief financial officer of several firms, including Brain, Combinature Biopharm, and November.
Former Applied Biosystems executive William Murray has joined the board of directors of MTS Systems. He is currently president and CEO of ReShape Medical. In the past, he held senior executive positions at Applied Biosystems, Viasys Healthcare, and Medtronic.